开发针对神经母细胞瘤的新型 GPC2 靶向放射诊疗和 CAR T 细胞疗法
Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.
嵌合抗原受体(CAR)的疗效取决于表面抗原的存在。
FRONTIER PAPERS
Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.
嵌合抗原受体(CAR)的疗效取决于表面抗原的存在。
CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.
CAR-T 细胞疗法利用经工程化改造以靶向特定肿瘤抗原的自体 T 细胞,是近年来儿童和成人血液系统恶性肿瘤治疗中最具前景的进展之一。
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
B 细胞急性淋巴细胞白血病 (B-ALL) 是儿童期最常见的癌症。
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
这些发现支持利用IL-18开发下一代细胞因子武装的CAR-NKT癌症免疫疗法。
Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control.
C7R在不依赖外源性信号的情况下促进了CAR-NK细胞在恶劣TMEs中的存活,但在体内导致抗肿瘤功能不佳。我们的数据揭示了持续性IL-7信号传导对CAR-NK细胞的有害作用,并为在尝试增强CAR-NK细胞抗肿瘤活性时合理应用细胞因子信号提供了见解。
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
人类自然杀伤T细胞(NKT)是一种先天样T淋巴细胞,越来越多地用于癌症免疫治疗。
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function.
自然杀伤T细胞(NKTs)是癌症免疫治疗的一个有前景的平台,但参与调控NKT治疗活性的基因很少被确定。
A novel GMP-manufactured medicinal product candidate composed of NK and γδ T cells as adjunct immunotherapy for hematopoietic stem cell transplantatio
我们实施了一种新的ATMP,不久将转化为临床实践,该疗法可能在移植后阶段作为有效的免疫疗法用于神经母细胞瘤和白血病儿科患者。
Photothermal Prussian blue nanoparticles generate potent multi-targeted tumor-specific T cells as an adoptive cell therapy.
基于普鲁士蓝纳米颗粒的光热治疗(PBNP-PTT)是一种有效的肿瘤治疗方法,能够引发抗肿瘤免疫反应。
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
第七届多利益相关方儿科战略论坛聚焦于针对儿童和青少年癌症的嵌合抗原受体(CAR)T细胞。
MEMBER ACCOUNT
登录成功会直接打开下一页。